ZA932455B - Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent - Google Patents

Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent

Info

Publication number
ZA932455B
ZA932455B ZA932455A ZA932455A ZA932455B ZA 932455 B ZA932455 B ZA 932455B ZA 932455 A ZA932455 A ZA 932455A ZA 932455 A ZA932455 A ZA 932455A ZA 932455 B ZA932455 B ZA 932455B
Authority
ZA
South Africa
Prior art keywords
phase
wit
treating cancer
antineoplastic agent
conjunctive therapy
Prior art date
Application number
ZA932455A
Other languages
English (en)
Inventor
Sai P Sunkara
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of ZA932455B publication Critical patent/ZA932455B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA932455A 1992-04-10 1993-04-05 Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent ZA932455B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86639992A 1992-04-10 1992-04-10

Publications (1)

Publication Number Publication Date
ZA932455B true ZA932455B (en) 1993-10-20

Family

ID=25347526

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA932455A ZA932455B (en) 1992-04-10 1993-04-05 Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent

Country Status (17)

Country Link
US (2) US20040102461A1 (es)
EP (1) EP0664708B1 (es)
JP (1) JP3713668B2 (es)
KR (1) KR100258668B1 (es)
AT (1) ATE170077T1 (es)
AU (1) AU667527B2 (es)
CA (1) CA2117891C (es)
DE (1) DE69320646T2 (es)
DK (1) DK0664708T3 (es)
ES (1) ES2123642T3 (es)
HU (1) HU219476B (es)
IL (1) IL105329A (es)
MX (1) MX9302038A (es)
NZ (1) NZ251211A (es)
TW (1) TW362971B (es)
WO (1) WO1993020825A1 (es)
ZA (1) ZA932455B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996001638A1 (en) * 1994-07-11 1996-01-25 Hoechst Marion Roussel, Inc. Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
WO1996001834A1 (fr) * 1994-07-12 1996-01-25 Yamasa Corporation 2'-desoxy-2'-(methylidene substitue ou non substitue)-4'-thionucleoside
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
ES2224430T3 (es) 1997-09-04 2005-03-01 Novoneuron Inc Noribogaina en el tratamiento del dolor y de la toxicomania.
US6544962B1 (en) 2000-11-02 2003-04-08 Matrix Pharmaceutical, Inc. Methods for treating cellular proliferative disorders
US20040002476A1 (en) * 2002-02-14 2004-01-01 Stuyver Lieven J. Modified fluorinated nucleoside analogues
WO2004042081A1 (de) * 2002-11-04 2004-05-21 Charité-Universitätsme Dizin Berlin Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
JP6049615B2 (ja) 2010-07-23 2016-12-21 デマークス・インコーポレイテッドDemerx,Inc. ノリボガイン組成物
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
AP2014007796A0 (en) 2011-12-22 2014-07-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス, インコーポレイテッド 置換ノルイボガイン
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them

Also Published As

Publication number Publication date
HU9402914D0 (en) 1995-01-30
AU667527B2 (en) 1996-03-28
US20040102461A1 (en) 2004-05-27
ES2123642T3 (es) 1999-01-16
CA2117891C (en) 1998-07-07
IL105329A (en) 1998-06-15
DE69320646T2 (de) 1999-01-14
EP0664708B1 (en) 1998-08-26
CA2117891A1 (en) 1993-10-28
EP0664708A1 (en) 1995-08-02
HU219476B (hu) 2001-04-28
TW362971B (en) 1999-07-01
IL105329A0 (en) 1993-08-18
ATE170077T1 (de) 1998-09-15
HUT71224A (en) 1995-11-28
WO1993020825A1 (en) 1993-10-28
AU3813193A (en) 1993-11-18
KR950700749A (ko) 1995-02-20
US20050032738A1 (en) 2005-02-10
EP0664708A4 (en) 1995-04-24
JPH07505653A (ja) 1995-06-22
KR100258668B1 (ko) 2000-07-01
NZ251211A (en) 1997-05-26
DK0664708T3 (da) 1998-11-02
DE69320646D1 (de) 1998-10-01
MX9302038A (es) 1993-10-01
JP3713668B2 (ja) 2005-11-09

Similar Documents

Publication Publication Date Title
ZA932455B (en) Method of treating cancer by conjunctive therapy wit 2'-halomethylidene derivatives and a S-phase ir M-phase specific antineoplastic agent
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
GEP20002146B (en) Therapeutic Peptide Derivatives
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
IL114530A0 (en) Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
IL101410A0 (en) Formulation for the treatment of cancer
EP0584034A3 (en) Conjugates of cytotoxic drugs for the treatment of neoplastic diseases.
GR3023645T3 (en) Treatment of liver cancer
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
AU1898792A (en) Treatment or therapeutic booth for energetic, cosmetic and medical purposes
ZA932303B (en) Medicament for the treatment of airways inflammation and airways hyperresponsiveness
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
NZ268039A (en) Use of efaroxan in treating parkinson's disease
AU4042795A (en) Treatment of non-small cell lung carcinoma
CA2103708A1 (en) Treatment of ovarian cancer
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
NO943795L (no) Metode for behandling av kreft ved konjunktiv terapi med 2'-halomethylidenderivater og et S-fase eller M-fase-spesifikt antineoplastisk middel
GB9024181D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
HU910944D0 (en) Apparatus for entering medical preparations by burning or smoking and process for treating the mucoviscidosis diseases
HU904161D0 (en) Medical preparations for treating asthmatic and other diseases attacking the respiratory organs
GB9123572D0 (en) Pharmaceutical compositions and methods for the treatment of malignancy
IL94263A0 (en) Therapeutic compositions for the treatment or prevention of snoring
HU903177D0 (en) Medical preparation for treating keratoconical changes of the cornea
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi